{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:07:52Z","timestamp":1791497272521,"version":"4.3.4"},"reference-count":50,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004385","name":"Universiteit Gent","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004385","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004727","name":"Vlaams Instituut voor Biotechnologie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004727","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.jaci.2019.02.028","type":"journal-article","created":{"date-parts":[[2019,3,12]],"date-time":"2019-03-12T22:31:39Z","timestamp":1552429899000},"page":"204-215","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":64,"title":["IL-33trap is a novel IL-33\u2013neutralizing biologic that inhibits allergic airway inflammation"],"prefix":"10.1016","volume":"144","author":[{"given":"Aurora","family":"Holgado","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Braun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elien","family":"Van Nuffel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sammy","family":"Detry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn J.","family":"Schuijs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Deswarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Vergote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mira","family":"Haegman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Griet","family":"Baudelet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurgen","family":"Haustraete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamida","family":"Hammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart N.","family":"Lambrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savvas N.","family":"Savvides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inna S.","family":"Afonina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudi","family":"Beyaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2019.02.028_bib1","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1378\/chest.13-2059","article-title":"Trends in the prevalence of asthma","volume":"145","author":"Sears","year":"2014","journal-title":"Chest"},{"key":"10.1016\/j.jaci.2019.02.028_bib2","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1016\/j.jaci.2015.12.1344","article-title":"Antisense molecules: a new class of drugs","volume":"137","author":"Potaczek","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.02.028_bib3","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.jaci.2016.03.006","article-title":"Toward precision medicine and health: opportunities and challenges in allergic diseases","volume":"137","author":"Galli","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.02.028_bib4","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.bcp.2018.01.010","article-title":"Dichotomous function of IL-33 in health and disease: from biology to clinical implications","volume":"148","author":"Braun","year":"2018","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.jaci.2019.02.028_bib5","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.imbio.2015.02.005","article-title":"IL-33\/ST2 axis controls Th2\/IL-31 and Th17 immune response in allergic airway diseases","volume":"220","author":"Vocca","year":"2015","journal-title":"Immunobiology"},{"key":"10.1016\/j.jaci.2019.02.028_bib6","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.jaci.2016.02.030","article-title":"IL-4 production by group 2 innate lymphoid cells promotes food allergy by blocking regulatory T-cell function","volume":"138","author":"Noval Rivas","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.02.028_bib7","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.immuni.2009.05.007","article-title":"Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases","volume":"31","author":"Luthi","year":"2009","journal-title":"Immunity"},{"key":"10.1016\/j.jaci.2019.02.028_bib8","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1111\/febs.13775","article-title":"Cell death and inflammation: the case for IL-1 family cytokines as the canonical DAMPs of the immune system","volume":"283","author":"Martin","year":"2016","journal-title":"FEBS J"},{"key":"10.1016\/j.jaci.2019.02.028_bib9","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jaci.2011.10.036","article-title":"Innate lymphoid cells responding to IL-33 mediate airway hyperreactivity independently of adaptive immunity","volume":"129","author":"Kim","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.02.028_bib10","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.immuni.2014.01.011","article-title":"Group 2 innate lymphoid cells are critical for the initiation of adaptive T helper 2 cell-mediated allergic lung inflammation","volume":"40","author":"Halim","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.jaci.2019.02.028_bib11","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.immuni.2005.09.015","article-title":"IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines","volume":"23","author":"Schmitz","year":"2005","journal-title":"Immunity"},{"key":"10.1016\/j.jaci.2019.02.028_bib12","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/0167-4889(93)90009-E","article-title":"Identification of the product of the murine ST2 gene","volume":"1178","author":"Takagi","year":"1993","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.jaci.2019.02.028_bib13","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nri.2016.134","article-title":"Mechanisms of immunomodulation by mammalian and viral decoy receptors: insights from structures","volume":"17","author":"Felix","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaci.2019.02.028_bib14","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.jaci.2012.11.028","article-title":"Decoding asthma: translating genetic variation in IL33 and IL1RL1 into disease pathophysiology","volume":"131","author":"Grotenboer","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.02.028_bib15","doi-asserted-by":"crossref","first-page":"5094","DOI":"10.4049\/jimmunol.0802387","article-title":"Increased expression of IL-33 in severe asthma: evidence of expression by airway smooth muscle cells","volume":"183","author":"Prefontaine","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2019.02.028_bib16","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.jaci.2009.12.935","article-title":"Increased IL-33 expression by epithelial cells in bronchial asthma","volume":"125","author":"Prefontaine","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.02.028_bib17","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1164\/rccm.201406-1039OC","article-title":"IL-33-dependent type 2 inflammation during rhinovirus-induced asthma exacerbations in\u00a0vivo","volume":"190","author":"Jackson","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2019.02.028_bib18","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jaci.2015.01.016","article-title":"Pediatric severe asthma with fungal sensitization is mediated by steroid-resistant IL-33","volume":"136","author":"Castanhinha","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.02.028_bib19","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jaci.2013.04.012","article-title":"IL-33 promotes airway remodeling in pediatric patients with severe steroid-resistant asthma","volume":"132","author":"Saglani","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.02.028_bib20","doi-asserted-by":"crossref","first-page":"5259","DOI":"10.1046\/j.1432-1033.2002.03237.x","article-title":"Extra terminal residues have a profound effect on the folding and solubility of a Plasmodium falciparum sexual stage-specific protein over-expressed in Escherichia coli","volume":"269","author":"Sati","year":"2002","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.jaci.2019.02.028_bib21","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ymeth.2014.11.024","article-title":"High-precision, automated integration of multiple isothermal titration calorimetric thermograms: new features of NITPIC","volume":"76","author":"Scheuermann","year":"2015","journal-title":"Methods"},{"key":"10.1016\/j.jaci.2019.02.028_bib22","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ymeth.2014.11.012","article-title":"SEDPHAT\u2014a platform for global ITC analysis and global multi-method analysis of molecular interactions","volume":"76","author":"Zhao","year":"2015","journal-title":"Methods"},{"key":"10.1016\/j.jaci.2019.02.028_bib23","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/nsmb.2367","article-title":"Allosteric competitive inactivation of hematopoietic CSF-1 signaling by the viral decoy receptor BARF1","volume":"19","author":"Elegheert","year":"2012","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.jaci.2019.02.028_bib24","doi-asserted-by":"crossref","first-page":"17.8.1","DOI":"10.1002\/0471143030.cb1708s23","article-title":"Isothermal titration calorimetry","volume":"23","author":"Velazquez-Campoy","year":"2004","journal-title":"Curr Protoc Cell Biol"},{"key":"10.1016\/j.jaci.2019.02.028_bib25","doi-asserted-by":"crossref","first-page":"14918","DOI":"10.1073\/pnas.1308651110","article-title":"Structural insights into the interaction of IL-33 with its receptors","volume":"110","author":"Liu","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaci.2019.02.028_bib26","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0003-2697(89)90213-3","article-title":"Rapid measurement of binding constants and heats of binding using a new titration calorimeter","volume":"179","author":"Wiseman","year":"1989","journal-title":"Anal Biochem"},{"key":"10.1016\/j.jaci.2019.02.028_bib27","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/nprot.2006.28","article-title":"Isothermal titration calorimetry to determine association constants for high-affinity ligands","volume":"1","author":"Velazquez-Campoy","year":"2006","journal-title":"Nat Protoc"},{"key":"10.1016\/j.jaci.2019.02.028_bib28","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1124\/jpet.114.222505","article-title":"Targeting IL-33 in autoimmunity and inflammation","volume":"354","author":"Theoharides","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jaci.2019.02.028_bib29","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jaci.2014.02.002","article-title":"Alternaria-derived serine protease activity drives IL-33-mediated asthma exacerbations","volume":"134","author":"Snelgrove","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.02.028_bib30","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.jaci.2017.01.015","article-title":"IL-33 dysregulates regulatory T cells and impairs established immunologic tolerance in the lungs","volume":"140","author":"Chen","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.02.028_bib31","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.jaci.2018.06.002","article-title":"A bispecific antibody strategy to target multiple type 2 cytokines in asthma","volume":"142","author":"Godar","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.02.028_bib32","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2011.406","article-title":"Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up","volume":"305","author":"Bartelds","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.jaci.2019.02.028_bib33","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/nrrheum.2013.4","article-title":"Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis","volume":"9","author":"van Schouwenburg","year":"2013","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jaci.2019.02.028_bib34","doi-asserted-by":"crossref","first-page":"3782","DOI":"10.1002\/art.22214","article-title":"Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab","volume":"54","author":"Bendtzen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2019.02.028_bib35","doi-asserted-by":"crossref","first-page":"e0175207","DOI":"10.1371\/journal.pone.0175207","article-title":"The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study","volume":"12","author":"Moots","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jaci.2019.02.028_bib36","doi-asserted-by":"crossref","first-page":"8765","DOI":"10.1073\/pnas.1601914113","article-title":"Alternative splicing of interleukin-33 and type 2 inflammation in asthma","volume":"113","author":"Gordon","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaci.2019.02.028_bib37","doi-asserted-by":"crossref","first-page":"20078","DOI":"10.1074\/jbc.M111.219089","article-title":"Identification of constitutively active interleukin 33 (IL-33) splice variant","volume":"286","author":"Hong","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jaci.2019.02.028_bib38","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1038\/s41598-018-21589-2","article-title":"Interleukin-33 is activated by allergen- and necrosis-associated proteolytic activities to regulate its alarmin activity during epithelial damage","volume":"8","author":"Scott","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.jaci.2019.02.028_bib39","doi-asserted-by":"crossref","first-page":"8327","DOI":"10.1038\/ncomms9327","article-title":"Oxidation of the alarmin IL-33 regulates ST2-dependent inflammation","volume":"6","author":"Cohen","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaci.2019.02.028_bib40","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.3748\/wjg.v17.i17.2181","article-title":"Soluble ST2: a new and promising activity marker in ulcerative colitis","volume":"17","author":"Diaz-Jimenez","year":"2011","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jaci.2019.02.028_bib41","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1164\/ajrccm.164.2.2008120","article-title":"Elevated soluble ST2 protein levels in sera of patients with asthma with an acute exacerbation","volume":"164","author":"Oshikawa","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2019.02.028_bib42","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1161\/01.CIR.0000047274.66749.FE","article-title":"Identification of serum soluble ST2 receptor as a novel heart failure biomarker","volume":"107","author":"Weinberg","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jaci.2019.02.028_bib43","first-page":"284","article-title":"Fusion-proteins as biopharmaceuticals\u2014applications and challenges","volume":"12","author":"Schmidt","year":"2009","journal-title":"Curr Opin Drug Discov Devel"},{"key":"10.1016\/j.jaci.2019.02.028_bib44","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.copbio.2011.06.012","article-title":"Strategies for extended serum half-life of protein therapeutics","volume":"22","author":"Kontermann","year":"2011","journal-title":"Curr Opin Biotechnol"},{"key":"10.1016\/j.jaci.2019.02.028_bib45","doi-asserted-by":"crossref","first-page":"337ra365","DOI":"10.1126\/scitranslmed.aaf1938","article-title":"Combinatorial targeting of TSLP, IL-25, and IL-33 in type 2 cytokine-driven inflammation and fibrosis","volume":"8","author":"Vannella","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaci.2019.02.028_bib46","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jaci.2016.08.026","article-title":"Combined blockade of the IL-13 and IL-33 pathways leads to a greater inhibition of type 2 inflammation over inhibition of either pathway alone","volume":"139","author":"Ramirez-Carrozzi","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.02.028_bib47","doi-asserted-by":"crossref","first-page":"14937","DOI":"10.1038\/ncomms14937","article-title":"Structure and antagonism of the receptor complex mediated by human TSLP in allergy and asthma","volume":"8","author":"Verstraete","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaci.2019.02.028_bib48","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.clinthera.2016.02.021","article-title":"Potential therapeutic aspects of alarmin cytokine interleukin 33 or its inhibitors in various diseases","volume":"38","author":"Arshad","year":"2016","journal-title":"Clin Ther"},{"key":"10.1016\/j.jaci.2019.02.028_bib49","doi-asserted-by":"crossref","first-page":"14919","DOI":"10.1038\/ncomms14919","article-title":"IL-33 contributes to sepsis-induced long-term immunosuppression by expanding the regulatory T cell population","volume":"8","author":"Nascimento","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaci.2019.02.028_bib50","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1172\/JCI30634","article-title":"IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system","volume":"117","author":"Sanada","year":"2007","journal-title":"J Clin Invest"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674919303483?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674919303483?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T09:20:18Z","timestamp":1758792018000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674919303483"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S0091674919303483"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2019.02.028","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IL-33trap is a novel IL-33\u2013neutralizing biologic that inhibits allergic airway inflammation","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2019.02.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}